SteriMax's business development strategy focuses on the acquisition and in-licensing of new product opportunities to enhance and build on our existing portfolio and to fuel the near to medium-term growth of our sales and marketing operations in North America. This external growth will be augmented by organic growth from our near-term development pipeline.

In addition to straight acquisition and in-licensing deals, opportunities exist to create synergies with international companies interested in entering the Canadian marketplace, through the formation of strategic alliances and Joint-Ventures, which can leverage the core competencies of SteriMax in North America.

What SteriMax brings to the table as a strategic partner is:

1. An established brand product portfolio to build upon and a near-term development pipeline
2. Proven track record in successful partnerships with innovator companies
3. Strong strategic partners in domestic and international markets
4. Strong partnerships with all major GPO's in Canada and in-depth expertise and long
   established relationships with the Canadian and US distribution/wholesale networks
5. In-house Regulatory and QA expertise
6. Privately financed and can make strategic decisions independent of outside controlling
   influences
7. We are a flexible, responsive and accessible organization that values and nurtures its
   strategic partnerships

At the moment, we are actively looking for new products to augment our continually growing portfolio. While our current products are focused on the hospital injectable market we are also interested in oral solid dosages, inhalation products and other drug delivery formats across all therapeutic classes.

We would be more than happy to discuss any potential product opportunities or strategic collaborations with you and to tell you more about our business development plans. You may contact any one of our senior management team directly to set up a meeting or send us an email at businessdevelopment@sterimaxinc.com.